Palvella Therapeutics Q2 Earnings Call Highlights

Palvella Therapeutics NASDAQ: PVLA said it remains on track to complete its new drug application submission for QTORIN rapamycin in microcystic lymphatic malformations, or mLM, during the second half of 2026, with potential FDA approval targeted for the first half of 2027.